References
- Cranovsky R, Schilling J, Faisst K et al. Health technology assessment in Switzerland. Int. J. Technol. Assess. Health Care 16(2), 576–590 (2000).
- Tilson L, O'Leary A, Usher C, Barry M. Pharmacoeconomic evaluation in Ireland: a review of the process. Pharmacoeconomics 28(4), 307–22 (2010).
- Cleemput I, van WP. History of health technology assessment in Belgium. Int. J. Technol. Assess. Health Care 25 (Suppl. 1), 82–87 (2009).
- van Oostenbruggen MF, Jansen RB, Mur K, Kooijman H. Penny and pound wise: pharmacoeconomics from a governmental perspective. Pharmacoeconomics 23(3), 219–226 (2005).
- Rochaix L, Xerri B. National Authority for Health: France. Issue Brief (Commonwealth Fund) 58, 1–9 (2009).
- Nuijten MJ, Szende A, Kosa J et al. Health care reform in six Central European countries. A focus on health economic requirements in the drug pricing and reimbursement processes. Eur. J. Health Econ. 4(4), 286–291 (2003).
- Nizankowski R, Wilk N. From idealistic rookies to a regional leader: the history of health technology assessment in Poland. Int. J. Technol. Assess. Health Care 25 (Suppl 1), 156–162 (2009).
- Nasser M, Sawicki P. Institute for Quality and Efficiency in Health Care: Germany. Issue Brief (Commonwealth Fund) 57, 1–12 (2009).
- Hjelmgren J, Berggren F, Andersson F. Health economic guidelines–similarities, differences and some implications. Value Health 4(3), 225–250 (2001).
- Jacobs P, Ohinmaa A, Brady B. Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. Pharmacoeconomics 23(2), 143–153 (2005).
- Knies S, Severens JL, Ament AJ, Evers SM. The transferability of valuing lost productivity across jurisdictions. Differences between national pharmacoeconomic guidelines. Value Health 13(5), 519–527 (2010).
- Sculpher MJ, Drummond MF. Analysis sans frontieres: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 24(11), 1087–1099 (2006).
- Drummond MF. Guidelines for pharmacoeconomic studies. The ways forward. Pharmacoeconomics 6(6), 493–497 (1994).
- Lopez-Bastida J, Oliva J, Antonanzas F et al. Spanish recommendations on economic evaluation of health technologies. Eur. J. Health Econ. 11(5), 513–520 (2010).
- Walter E, Zehetmayr S. Guidelines zur gesundheitsökonomischen Evaluation Konsenspapier [Guidelines for health-economic evaluations in Austria]. Wien. Med. Wochenschr. 156(23–24), 628–632 (2006).
- Manual for the standardization of clinical and economic evaluation. Berne, Switzerland: BSV (Swiss Federal Social Insurance Office); 2000.
- Capri S, Ceci A, Terranova L et al. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inf. J. 35, 189–201 (2001).
- Cleemput I, van WP, Huybrechts M, Vrijens F. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 12(4), 441–449 (2009).
- Szende A, Mogyorosy Z, Muszbek N et al. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Eur. J. Health Econ. 3(3), 196–206 (2002).
- Mattke S, Balakrishnan A, Bergamo G, Newberry SJ. A review of methods to measure health-related productivity loss. Am. J. Manag. Care 13(4),211–217 (2007).
- van Exel J, Bobinac A, Koopmanschap M, Brouwer W. The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. Expert Rev. Pharmacoecon. Outcomes Res. 8(6), 557–561 (2008).
- Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Caring for and caring about: disentangling the caregiver effect and the family effect. J. Health Econ. 29(4), 549–556 (2010).
- Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Health effects in significant others: separating family and care-giving effects. Med. Decis. Making 31(2), 292–298 (2011).
- Dixon S, Walker M, Salek S. Incorporating carer effects into economic evaluation. Pharmacoeconomics 24(1), 43–53 (2006).
- Hoefman RJ, van Exel NJ, Looren de JS et al. A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. Qual. Life Res. 20(6), 875–887 (2011).
- Brouwer W, van Exel N, Baltussen R, Rutten F. A dollar is a dollar is a dollar – or is it? Value Health 9(5), 341–347 (2006)
- Roy S, Madhavan SS. Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions. Pharmacoeconomics 26(4), 281–296 (2008).
- Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur. J. Health Econ. 10(4), 357–359 (2009).
- van der Zee J, Kroneman MW. Bismarck or Beveridge: a beauty contest between dinosaurs. BMC Health Serv. Res. 7, 94 (2007).
- Johannesson M. A note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy 33(1), 59–66 (1995).
- Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 2(1),1–4 (1992).
- Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J. Health Econ. 24(4), 751–773 (2005).
- Keech M. Using health outcomes data to inform decision-making: a pharmaceutical industry perspective. Pharmacoeconomics 19 (Suppl 2), 27–31 (2001).
- Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Pharmacoeconomics 18(1), 55–62 (2000).
- Atthobari J, Bos JM, Boersma C et al. Adherence of pharmacoeconomic studies to national guidelines in the Netherlands. Pharm. World Sci. 27(5), 364–370 (2005).
- Longworth L, Sculpher MJ, Bojke L, Tosh JC. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence. Int. J. Technol. Assess. Health Care 27(2), 180–187 (2011).
Websites
- http://www.ispor.org/peguidelines
- da Silva EA, Pinto CG, Sampaio C et al. Guidelines for economic drug evaluation studies. Autoridade Nacional do Medicamento e Produtos de Saúde (INFARMED) [Portuguese National Authority of Medicines and Health Products] (1998). www.infarmed.pt/portal/page/portal/INFARMED/ENGLISH/PCAEC04_vering.pdf ( Accessed 21 March 2011)
- Guidelines for conducting Health Technology Assessment (HTA). Version 2.1. Warsaw, Poland: Agencji Oceny Technologii Medycznych [Agency for Health Technology Assessment] (2009). www.aotm.gov.pl/index.php?id=13 ( Accessed 21 March 2011)
- PE Guidelines Around the World: Poland. International Society for Pharmacoeconomics and Outcomes Research; 10 May (2011). www.ispor.org/PEguidelines/countrydet.asp?c=16&t=2 ( Accessed 26 October 2011)
- Guide méthodologique pour l'évaluation économique des stratégies de santé [French guidelines for the economic evaluation of health care technologies]. Paris, France: Collège des Économistes de la Santé [French Health Economists Association]; July (2003). www.ces-asso.org/docs/France_Guidelines_HE_Evaluation.PDF ( Accessed 18 March 2011)
- General methods for the assessment of the relation of benefits to costs. Version 1.0. Köln, Germany: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care] (2009). www.iqwig.de/index.736.en.html ( Accessed 21 March 2011)
- Working paper: cost estimation. Version 1.0. Köln, Germany: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care] (2009). www.iqwig.de/index.736.en.html ( Accessed 21 March 2011)
- Working paper: modelling. Version 1.0. Köln, Germany: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care] (2009). www.iqwig.de/index.736.en.html ( Accessed 21 March 2011)
- Vägledning för företagen. Hur man ansöker om subvention och pris hos LFN [Guidelines for companies: The Swedish Pharmaceutical Benefits Board (LFN)]. Tandvårds- och läkemedelsförmånsverket [Swedish Dental and Pharmaceutical Benefits Agency] (2008). www.tlv.se/lakemedel/ansok-om-pris-eller-subvention/ ( Accessed 22 March 2011)
- Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie [Guidelines for pharmacoeconomic research, updated version]. Diemen, The Netherlands: College voor zorgverzekeringen [Health Care Insurance Board] (2006). www.cvz.nl/zorgpakket/cfhagenda/commissie/farmaco-economisch+onderzoek/farmaco-economisch+onderzoek.html
- Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence (2008). www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp ( Accessed 23 March 2011)
- Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. Statens legemiddelverk [Norwegian Medicines Agency] (2005). www.legemiddelverket.no/templates/InterPage____25644.aspx ( Accessed 21 March 2011)
- Guidelines for the economic evaluation of health technologies in Ireland (2010). www.hiqa.ie/media/pdfs/HTA_Economic_Guidelines_2010.pdf ( Accessed 21 March 2011)
- Guidelines for inclusion of drug costs in pharmacoeconomic evaluations. Version 1.6. National Centre for Pharmacoeconomics (2010). www.ncpe.ie/document.php?cid=26&sid=139&docid=190 ( Accessed 21 March 2011)
- Guidance to manufacturers for completion of New Product Assessment Form (NPAF). Glasgow, Scotland: Scottish Medicines Consortium (2011). www.scottishmedicines.org.uk/Submission_Process/Submission_Guidance_and_Templates_for_Industry/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission ( Accessed 23 March 2011)
- Metodická pomôcka k vyhláške Ministerstva zdravotníctva Slovenskej republiky è. 343/2008 Z. z. o podrobnostiach farmako-ekonomického rozboru lieku [Guideline to the Decree of the Ministry of Health of the Slovak Republic no. 343/2008 Z. z.: the details of pharmacoeconomic analysis of drugs]. Ministerstvo zdravotníctva Slovenskej republiky [Slovak Republic Ministry of Health] (2009). www.health.gov.sk/?farmako-ekonomicky-rozbor-lieku ( Accessed 22 March 2011)
- Cleemput I, Van Wilder P, Vrijens F et al. Guidelines for pharmacoeconomic evaluations in Belgium. KCE reports 78C. Brussels, Belgium: Federaal Kenniscentrum voor de gezondheidszorg – Centre fédéral d'expertise des soins de santé (2008). www.kce.fgov.be/index_en.aspx?SGREF=5215&CREF=11009 ( Accessed 18 March 2011)
- Behmane D, Lambot K, Irs A et al. N. Baltic guideline for economic evaluation of pharmaceuticals (pharmacoeconomic analysis). Eesti Haigekassa [Estonian Health Insurance Fund] (2002). www.haigekassa.ee/eng/health-insurance-in-estonia/medicinal-products/pharmacoeconomic-analysis ( Accessed 21 March 2011)
- Pravilnik: o mjerilima za stavljanje lijekova na osnovnu i dopunsku listu lijekova Hrvatskog Zavoda za Zdravstveno Osiguranje [Ordinance: The scale of the marketing authorization of the initial and supplementary medicine, Croatian Institute For Health Insurance]. Zagreb, Croatia: Ministarstvo Zdravstva i Socijalne Skrbi [Croatian Ministry of Health and Social Welfare] (2009). http://narodne-novine.nn.hr/clanci/sluzbeni/2009_12_155_3832.html ( Accessed 27 March 2011)
- Alban A, Keiding H, Søgaard J. Retningslinjer for udarbejdelse af økonomiske analyser af lægemidler. Bilag 1 i Sundhedsministeriet: Udfordringer på lægemiddelområdet. Betænkning afgivet af Sundhedsministeriets Medicinudvalg [Guidelines for the preparation of economic analyses of drugs. Appendix 1 in the Ministry of the Interior and Health: Challenges in the drug field. Report from the drug committee of the Ministry of the Interior and Health]. Copenhagen: Sundhedsministeriets [Ministry of the Interior and Health] (1998). www.sum.dk/Aktuelt/Publikationer/Publikationer/Udfordringer_paa_laegemiddelomraadet/Bilag%201.aspx ( Accessed 18 March 2011)
- Health Technology Assessment Handbook 2007. Copenhagen: Danish Centre for Health Technology Assessment, National Board of Health (2008). www.sst.dk/~/media/Planlaegning%20og%20kvalitet/MTV%20metode/HTA_Handbook_net_final.ashx ( Accessed 18 March 2011)
- Ohje terveystaloudellisen selvityksen laatimiseksi (Liite). Sosiaali- ja terveysministeriön asetus lääkkeiden hintalautakunnalle tehtävästä hakemuksesta ja hintailmoituksesta [Guidelines for preparing a health economic evaluation. Appendix in Decree of the Ministry of Social Affairs and Health on applications and price notifications made to the Pharmaceuticals Pricing Board]. Helsinki, Finland: Sosiaali- ja terveysministeriön [Ministry of Social Affairs and Health] (2009). www.stm.fi/c/document_library/get_file?folderId=71837&name=DLFE-10037.pdf ( Accessed 18 March 2011)
- The standardization system in the Russian Federation health care system: clinico-economic studies. General provisions. ISPOR (2002). www.ispor.org/peguidelines/source/PE%20guideline_Russian%20Federation.pdf ( Accessed 21 March 2011)
- Edling A, Stenberg AM. Läkemedelsförmånsnämndens allmänna råd om ekonomiska utvärderingar (LFNAR 2003:2) [General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2)]. Tandvårds- och läkemedelsförmånsverket [Swedish Dental and Pharmaceutical Benefits Agency] (2003). www.tlv.se/tlv/regelverk/allmanna-rad/ ( Accessed 22 March 2011).
- http://www.eunethta.eu/Public/About_EUnetHTA/